DK2094849T3 - Langsigtet sygdomsmodifikation ved anvendelse af immunstimulatoriske oligonukleotider - Google Patents

Langsigtet sygdomsmodifikation ved anvendelse af immunstimulatoriske oligonukleotider Download PDF

Info

Publication number
DK2094849T3
DK2094849T3 DK07871436.7T DK07871436T DK2094849T3 DK 2094849 T3 DK2094849 T3 DK 2094849T3 DK 07871436 T DK07871436 T DK 07871436T DK 2094849 T3 DK2094849 T3 DK 2094849T3
Authority
DK
Denmark
Prior art keywords
iss
sequence
composition
antigen
tcg
Prior art date
Application number
DK07871436.7T
Other languages
English (en)
Inventor
Edith Hessel
Robert L Coffman
Original Assignee
Dynavax Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dynavax Tech Corp filed Critical Dynavax Tech Corp
Application granted granted Critical
Publication of DK2094849T3 publication Critical patent/DK2094849T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Claims (14)

1. Sammensætning, omfattende en virksom mængde af en immunstimulato-risk sekvens (ISS), hvor ISS'en er en CpG-indeholdende ISS til anvendelse ved den langsigtede sygdomsmodifikation af astma ved flere indgivelser af sammensætningen, hvor ISS'en indgives mindst 5 gange.
2. Sammensætning til anvendelse ifølge krav 1, hvor ISS'en indgives mindst 8 gange.
3. Sammensætning til anvendelse ifølge krav 1 eller 2, hvor de flere indgivelser sker på en ugebasis.
4. Sammensætning til anvendelse ifølge krav 1 eller 2, hvor de flere indgivelser sker hver anden uge.
5. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den langsigtede sygdomsmodifikation er en formindskelse af en Th2-reaktion i individet.
6. Sammensætning til anvendelse ifølge krav 5, hvor formindskelsen af en Th2-reaktion i individet er en formindskelse af et hvilket som helst af cytoki-nerne, udvalgt fra IL-4, IL-5, IL-10 og IL-13.
7. Sammensætning til anvendelse ifølge krav 5, hvor en formindskelse af en Th2-reaktion i et individ er en formindskelse af en eosinofil infiltration i luftvejene.
8. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor en modifikation varer ved i mindst 8 uger efter den sidste indgivelse af ISS'en.
9. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor den langsigtede sygdomsmodifikation varer ved i mindst 13 uger efter den sidste indgivelse af ISS'en.
10. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor behandlingen resulterer i en langsigtet sygdomsmodifikation af astma, hvor astmaen er en allergisk astma.
11. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor ISS'en er 1018 ISS.
12. Sammensætning til anvendelse ifølge et hvilket som helst af kravene 1 til 10, hvor ISS'en er 5'-Nx(TCG(Nq))yNw(X1X2CGX2'Xi'(CG)p)z, hvor N er nukle-osider med x = 0-3, y = 1 -4, w = -2, -1,0,1 eller 2, p= 0 eller 1, q = 0, 1 eller 2, og z = 1-20, hvor X^ og XV, X2 og X2' er selvkomplementære, og hvor 5' T af (TCG(Nq))y-sekvensen er 0-3 baser fra den 5'-ende af polynukleotidet.
13. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor ISS'en er en ukonjugeret ISS.
14. Sammensætning til anvendelse ifølge et hvilket som helst af de foregående krav, hvor ISS'en omfatter phosphorothioatbindinger.
DK07871436.7T 2006-11-09 2007-11-09 Langsigtet sygdomsmodifikation ved anvendelse af immunstimulatoriske oligonukleotider DK2094849T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86508906P 2006-11-09 2006-11-09
PCT/US2007/084358 WO2008073661A2 (en) 2006-11-09 2007-11-09 Long term disease modification using immunostimulatory oligonucleotides

Publications (1)

Publication Number Publication Date
DK2094849T3 true DK2094849T3 (da) 2014-03-24

Family

ID=39512389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07871436.7T DK2094849T3 (da) 2006-11-09 2007-11-09 Langsigtet sygdomsmodifikation ved anvendelse af immunstimulatoriske oligonukleotider

Country Status (10)

Country Link
US (1) US8252757B2 (da)
EP (1) EP2094849B1 (da)
JP (2) JP5714818B2 (da)
CN (2) CN101636495A (da)
AU (1) AU2007333368C1 (da)
CA (1) CA2669137A1 (da)
DK (1) DK2094849T3 (da)
ES (1) ES2454175T3 (da)
PL (1) PL2094849T3 (da)
WO (1) WO2008073661A2 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100334228C (zh) * 2001-06-21 2007-08-29 戴纳瓦克斯技术公司 嵌合免疫调制化合物及其使用方法
AU2003259827B2 (en) * 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
EP1992635B1 (en) * 2002-12-23 2012-02-08 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP2094849B1 (en) 2006-11-09 2014-01-08 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
WO2009140626A2 (en) 2008-05-15 2009-11-19 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
DE102009034779A1 (de) 2009-07-25 2011-02-03 Emc Microcollections Gmbh Synthetische Analoga bakterieller Lipopeptide und ihre Anwendung zur Therapie und Prophylaxe allergischer Erkrankungen
CA2810928A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
CN104321333A (zh) 2012-03-21 2015-01-28 沃泰克斯药物股份有限公司 硫代氨基磷酸酯核苷酸前药的固体形式
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
JP7128477B2 (ja) * 2017-02-07 2022-08-31 京都府公立大学法人 病原性グラム陰性菌に対するワクチン
US11559561B2 (en) * 2019-01-07 2023-01-24 Translate Bio, Inc. Composition and methods for treatment of primary ciliary dyskinesia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) * 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4948882A (en) * 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4650675A (en) * 1983-08-18 1987-03-17 The Children's Medical Center Corporation Oligonucleotide conjugates
US5118802A (en) * 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US4849513A (en) * 1983-12-20 1989-07-18 California Institute Of Technology Deoxyribonucleoside phosphoramidites in which an aliphatic amino group is attached to the sugar ring and their use for the preparation of oligonucleotides containing aliphatic amino groups
US5118800A (en) * 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5015733A (en) * 1983-12-20 1991-05-14 California Institute Of Technology Nucleosides possessing blocked aliphatic amino groups
US5093232A (en) * 1985-12-11 1992-03-03 Chiron Corporation Nucleic acid probes
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes
US5124246A (en) * 1987-10-15 1992-06-23 Chiron Corporation Nucleic acid multimers and amplified nucleic acid hybridization assays using same
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5460831A (en) * 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5452496A (en) * 1994-02-03 1995-09-26 Schuller International, Inc. Vacuum assisted accumulator and process of collecting microfiber
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
JP4359654B2 (ja) 1996-01-30 2009-11-04 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア 抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
DK1009413T3 (da) * 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
WO2000061151A2 (en) 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040132677A1 (en) * 2001-06-21 2004-07-08 Fearon Karen L. Chimeric immunomodulatory compounds and methods of using the same-IV
AU2003259827B2 (en) * 2002-08-12 2008-09-04 Dynavax Technologies Corporation Immunomodulatory compositions, methods of making, and methods of use thereof
EP1992635B1 (en) * 2002-12-23 2012-02-08 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7718622B2 (en) 2005-03-04 2010-05-18 Dynavax Technologies Corporation Compositions comprising structurally stable conjugate molecules
EP2094849B1 (en) 2006-11-09 2014-01-08 Dynavax Technologies Corporation Long term disease modification using immunostimulatory oligonucleotides

Also Published As

Publication number Publication date
CA2669137A1 (en) 2008-06-19
CN101636495A (zh) 2010-01-27
EP2094849A2 (en) 2009-09-02
WO2008073661A3 (en) 2009-02-12
AU2007333368A1 (en) 2008-06-19
PL2094849T3 (pl) 2014-06-30
JP2010509371A (ja) 2010-03-25
ES2454175T3 (es) 2014-04-09
WO2008073661A2 (en) 2008-06-19
AU2007333368C1 (en) 2014-03-13
US8252757B2 (en) 2012-08-28
EP2094849B1 (en) 2014-01-08
JP6023142B2 (ja) 2016-11-09
CN104857512A (zh) 2015-08-26
JP2015028066A (ja) 2015-02-12
JP5714818B2 (ja) 2015-05-07
AU2007333368B2 (en) 2013-07-18
US20090068208A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
DK2094849T3 (da) Langsigtet sygdomsmodifikation ved anvendelse af immunstimulatoriske oligonukleotider
AU2009246169B2 (en) Long term disease modification using immunostimulatory oligonucleotides
KR101309501B1 (ko) 면역자극성 서열 올리고뉴클레오타이드 및 이의 이용방법
KR100881923B1 (ko) 면역자극 폴리뉴클레오티드 및 그것의 사용 방법
EP1551376A2 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
AU2002231336A1 (en) Immunomodulatory polynucleotides and methods of using the same